retatrutide mechanism gip glp-1 glucagon triple agonist Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing A review of an investigational

A few studies have used mammalian calcitonin to investigate effects beyond those related to calcium and bone metabolism

Results showed that combination treatment with lower dose of metformin (0.1 mmol/L) and liraglutide (3 nmol/L) eliminated the inhibitory effects of PA (0.5 mmol/L) on the protein levels of GLP-1R (marginally) and p-PKA (completely)

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis

Any dietary changes should be implemented as part of a comprehensive management plan that includes regular monitoring of glycaemic control, weight, and treatment response

Clinical trials, including phase 2 and 3 studies, have reported significant improvements in liver histology, including MASH resolution and decreased hepatic fat content, with GLP-1RA therapy (6, 7)